about
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy.Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent RestenosisErythropoietin and the heart: facts and perspectives.IGF-1 and atherothrombosis: relevance to pathophysiology and therapy.Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors.Polypharmacy in heart failure patients.Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice.Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease.Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy.QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal.Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy.Spatial QT Dispersion Predicts Nonsustained Ventricular Tachycardia and Correlates with Confined Systodiastolic Dysfunction in Hypertrophic Cardiomyopathy.Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.[Role of adherence to long-term drug therapy in patients with cardiovascular disease: an Italian intersocietary consensus document].Erythropoiesis-stimulating agents in heart failure: leave it or re-take it?Restrictive cardiomyopathy and pseudoxanthoma elasticum skin lesionsHeart Failure Progression in Hypertrophic Cardiomyopathy – Possible Insights From Cardiopulmonary Exercise Testing –Myocardial Repolarization Dispersion and Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy
P50
Q33167286-E7C5C1C0-C8CB-489B-9154-CE1232CF30DFQ36950156-A5966FC0-4DEC-4ABB-992E-F1C2F689F1FEQ37798565-80A3CD5C-7840-4977-A3FD-8B8768F2B36EQ37829755-F6453A1F-3846-4250-BDE2-30CC07D119C6Q38082019-CAD13602-40B6-40E9-ACAD-E8C55A9027EEQ38184967-B7B2EBA7-68FC-44DD-B47C-6893C2E58531Q38420970-3263AA70-492D-4A53-A588-3DE001D0B976Q38430611-CA333A7C-4C3F-4A39-B8E5-27CCAE22D739Q38667487-CD4AA936-6F11-481E-BF0E-D76E017AC75DQ38877523-3B17215C-1DE6-4B01-BF73-0879566CCBF0Q39368546-A8184CEB-DACC-4CD6-80AD-B8CFB9792643Q39368554-87A33630-8F60-4CBB-B646-64A6A472CB05Q40019666-0CA58FB4-ECED-417A-B83E-ACFAA38F0C74Q40996134-0E8DE7FB-8D45-4002-89B4-58086564625FQ46596820-FEAE7DFE-663C-4D3C-A2BA-D36D98F16742Q48805784-F39F447E-EA7B-483F-BDE7-FCC456046023Q61865863-47C75D01-8E14-4D5C-B1E3-39C6B88F08F7Q61865875-E73DA8F2-F72B-4B99-9E26-201786682FCDQ62024837-E51A33C4-1744-4EED-B151-27F774CDD548Q62024844-50D70CEF-A7E4-406D-A51C-DB227E5A0489
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vittoria Mastromarino
@ast
Vittoria Mastromarino
@en
Vittoria Mastromarino
@es
Vittoria Mastromarino
@nl
type
label
Vittoria Mastromarino
@ast
Vittoria Mastromarino
@en
Vittoria Mastromarino
@es
Vittoria Mastromarino
@nl
prefLabel
Vittoria Mastromarino
@ast
Vittoria Mastromarino
@en
Vittoria Mastromarino
@es
Vittoria Mastromarino
@nl
P106
P1153
36721525000
P31
P496
0000-0001-6071-7386